Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on its stellar segmental performance in Q3.
Here's Why You Should Hold on to Phibro (PAHC) Stock Now
by Zacks Equity Research
Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.
Hill-Rom Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Hill-Rom (HRC) is optimistic about maintaining its growth momentum on several recent developments.
Amedisys Completes Asana Hospice Acquisition, Expands Network
by Zacks Equity Research
Amedisys (AMED) closes Asana takeover to strengthen its hospice care network.
Illumina Stock Slips on Pacific Biosciences Deal Termination
by Zacks Equity Research
Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.
Teleflex Hits New 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.
Thermo Fisher Rides on New Product Suite, Currency Woes Stay
by Zacks Equity Research
Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.
Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod
by Zacks Equity Research
Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.
Hologic (HOLX) Divests Cynosure to Focus on Women's Health
by Zacks Equity Research
Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.
Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.
Here's Why You Should Hold on to Insulet (PODD) Stock Now
by Zacks Equity Research
Investors can retain Insulet (PODD) stock for now on the back of its solid prospects.
Here's Why You Should Hold on to Intersect ENT (XENT) for Now
by Zacks Equity Research
Investors can retain Intersect ENT (XENT) stock for now, courtesy of its solid prospects.
Bio-Rad Gains on New Product Portfolio Despite Currency Woes
by Zacks Equity Research
Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.
Here's Why You Should Add NuVasive Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Syneos Health (SYNH) gains from several positive developments.
Edwards (EW) Rides on Innovation Despite Regulatory Issues
by Zacks Equity Research
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
Here's Why You Should Hold on to Thermo Fisher Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar segmental performance.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investors can retain Hill-Rom (HRC) in their portfolio, courtesy of solid prospects.
Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry
by Zacks Equity Research
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
Nevro (NVRO) Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Nevro (NVRO) gains from several positive developments.
Product Launches Aid Intersect ENT (XENT) Despite Cost Woes
by Zacks Equity Research
Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts
by Zacks Equity Research
Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.
Zimmer Biomet Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.
Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises
by Zacks Equity Research
Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.